Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001172 | Arthritis, Rheumatoid NIH | 0.27 |
| D001168 | Arthritis NIH | 0.23 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001370 | Rheumatoid arthritis HPO | 0.27 |
| HP:0001369 | Arthritis HPO | 0.23 |
Navigate: Correlations HPO
There is one clinical trial.
This randomized, double-blind, placebo-controlled trial will enroll subjects with a clinical diagnosis of COVID-19 confirmed by laboratory testing. Eligible subjects will be randomized to either CAP-1002 or placebo in a 1:1 ratio. Intravenous administration of CAP-1002 or placebo will occur at the clinical site on Day 1 and Day 7 (± 1 day) for a maximum of 2 doses, based on clinical course. Subjects will complete Screening, a Treatment Phase and a Follow-up Phase. The Treatment Phase is variable based on each subject's clinical status while the subject remains in the hospital and will contain either one or two treatment periods. Baseline safety and efficacy assessments will be conducted prior to the first infusion. Follow-up will be conducted on Day 15 and Day 30 from the first infusion in Treatment Period 1. Subjects will be observed during the index hospitalization and monitored for outcome and safety. Transthoracic echocardiograms will be performed when indicated by clinical or laboratory evidence of cardiac involvement during the index hospitalization. Use of any concomitant medications to treat COVID-19 will be documented. Stopping rules on the subject-level and study-level have been defined to ensure subjects are not exposed to significant risk. Oversight of the trial will be provided by independent Clinical Event Committee (CEC), Data Safety Monitoring Board (DSMB), and Medical Monitor.
Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports